Clinical trial · no report yet · Phase 3
CheckMate 7FL
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
- NCT04109066 ↗
- Completed
- Bristol-Myers Squibb
- 93 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 37 | |
| Podcasts | 29 | |
| YouTube | 27 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Breast Cancer
- Interventions
- nivolumab; paclitaxel (PTX); nivolumab placebo; anthracycline; cyclophosphamide; Endocrine Therapy; Surgery
- Arms
- Arm A: Nivolumab combined with neoadjuvant CT and adjuvant ET · Experimental
- Arm B: Placebo combined with neoadjuvant CT and then adjuvant ET · Placebo comparator
- Enrollment
- 521
- Primary outcomes
- Pathological Complete Response (pCR) Rate
- Sponsor
- Bristol-Myers Squibb
- Start
- Nov 18, 2019
- Primary completion
- Jan 16, 2023
- Results posted
- Yes
- Registry record
- NCT04109066 · updated Jan 8, 2025
Publications
linked from the registry- Loi S, Salgado R, Curigliano G, Romero Diaz RI, Delaloge S, Rojas Garcia CI, Kok M, Saura C, Harbeck N, Mittendorf EA, Yardley DA, Suarez Zaizar A, Caminos FR, Ungureanu A, Reinoso-Toledo JG, Guarneri V, Egle D, Ades F, Pacius M, Chhibber A, Chandra R, Nathani R, Spires T, Wu JQ, Pusztai L, McArthur H. Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. Nat Med. 2025 Feb;31(2):433-441. doi: 10.1038/s41591-024-03414-8. Epub 2025 Jan 21. PubMed 39838118
- Schlam I, Corti C, Sammons S, Mittendorf EA, Tolaney SM. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. Expert Opin Biol Ther. 2024 Jun;24(6):511-520. doi: 10.1080/14712598.2024.2370395. Epub 2024 Jun 24. PubMed 38913933